2,168 reports of this reaction
2.2% of all CONJUGATED ESTROGENS reports
#8 most reported adverse reaction
OFF LABEL USE is the #8 most commonly reported adverse reaction for CONJUGATED ESTROGENS, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 2,168 FDA adverse event reports linking CONJUGATED ESTROGENS to OFF LABEL USE. This represents approximately 2.2% of all 100,524 adverse event reports for this drug.
Patients taking CONJUGATED ESTROGENS who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for CONJUGATED ESTROGENS, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for CONJUGATED ESTROGENS:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 2,168 FDA reports for CONJUGATED ESTROGENS. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.2% of all adverse event reports for CONJUGATED ESTROGENS, making it a notable side effect.
If you experience off label use while taking CONJUGATED ESTROGENS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.